Panitumumab nonlinear population PK
Reference paper ↗A two-compartment population PK model coupling panitumumab distribution to parallel linear and saturable Michaelis–Menten elimination.
- Therapeutic
- Panitumumab
- Modality
- Monoclonal antibody
- Target
- EGFR / ERBB1
- Disease
- Cancer therapy with EGFR-targeted panitumumab
- Model type
- PopPK
Complete model workspace
Checking workspace access…
- Parameters
- 6
- States
- 4
- Equations
- 4
- Derived outputs
- 8
Explore this model
Choose a starting point to view its result. Adjust key model inputs when you want to explore a different outcome.
Starting configuration
Typical FFCD0904 3 mg/kg every 2 weeks with AUC
Typical FFCD0904 3 mg/kg every 2 weeks with AUC
How do linear and saturable elimination jointly shape panitumumab concentration and exposure? Explore this intervention regimen through Central panitumumab concentration, Peripheral panitumumab concentration, Linear elimination, Saturable elimination, Cumulative panitumumab exposure.
Starting result
This result reflects the starting settings. Run your changes to update it.
Result preview could not load
The generated result could not be loaded. The inputs remain available below.
Starting configuration
Time: 0–70 day; step 0.25
| Input | Default | Available range |
|---|---|---|
| Systemic clearance | 0.4 L/day | 0.2–0.6 L/day |
| Central distribution volume | 2.51 L | 1.255–3.765 L |
| Intercompartmental clearance | 0.17 L/day | 0.085–0.255 L/day |
| Peripheral distribution volume | 2.91 L | 1.455–4.365 L |
| Maximum elimination rate | 4.26 mg/day | 2.13–6.39 mg/day |
Expected readouts
Central panitumumab concentration · Peripheral panitumumab concentration · Linear elimination · Saturable elimination · Exposure (AUC) (mg*day/L)
Adjustable model parameters
This public explorer exposes 5 curated parameters. Sign in to edit all 6 declared model parameters.
More key parameters (1)
How the model represents the biology
A two-compartment population PK model coupling panitumumab distribution to parallel linear and saturable Michaelis–Menten elimination.
Solid arrows show modeled movement or change; two-headed arrows show reversible exchange; dashed arrows show modulation without material transfer.
Model scope: EGFR binding or occupancy, target amount or internalization, tumor response, and body-composition effects are not represented in this released runtime.
Modeled relationships (5)
- IV panitumumab → Central exposure: IV input (flow)
- Central exposure ↔ Peripheral pool: distribution (reversible exchange)
- Central exposure → Linear elimination: linear CL (loss)
- Central exposure → Saturable elimination: Vmax / Km (loss)
- Central exposure → Cumulative exposure: integrates C (production)
Modeled relationships: IV panitumumab to Central exposure: IV input (flow); Central exposure reversibly exchanges with Peripheral pool: distribution (reversible exchange); Central exposure to Linear elimination: linear CL (loss); Central exposure to Saturable elimination: Vmax / Km (loss); Central exposure to Cumulative exposure: integrates C (production).
Primary readouts: Central panitumumab concentration; Peripheral concentration; Linear elimination; Saturable elimination; Cumulative exposure.
Related models
Research use only — not for patient-specific prediction or dosing advice.
